Abstract

Background:

Testosterone (T) deficiency (TD) in men and women and estrogen (E) deficiency (ED) in women increasingly affects the overall health and quality of life of patients. T implants have seen increased utilization over the past decade. We evaluated continuation rates and adverse events that occurred during T therapy by reviewing practitioner reported data on compressed human-identical T implants for the treatment of TD in both men and women collected over 7 years.
 

Methods:

This was a retrospective review of data collected prospectively from men and women from 2012 and 2019. Men who had the clinical syndrome of TD received subcutaneous T implant therapy. Women who presented with symptoms of TD and/or ED underwent T implant and/or estradiol implant therapy. The clinics spanned multiple specialties including obstetrics and gynecology, internal medicine, family practice, and urology. Data were entered into a secure, custom tracking App, using Azure App Services and MS SQL Database integrated with a proprietary dosing site and industry-leading Pharmacy Dispensing software (BioTracker®).
 

Results:

Over the 7 years, 1,204,012 subcutaneous implant procedures were performed for 376,254 patients; 85% of the procedures were performed in women. Of the women, 54% of were premenopausal, and 46% were postmenopausal. The overall continuation rate after two insertions was 93%. The overall complication rate was <1%. Most common secondary response reported was pellet extrusion, which was more common in men (<3%) than women (<1%).
 

Conclusions:

This study is the largest reported retrospective study to evaluate the continuation and complication rates of T pellet implants. The safety of subcutaneous hormone pellet implants in men and women appears to be better than other routes of administration of bioidentical hormone replacement therapy. Further investigations on short- and long-term benefits of this modality are ongoing and could expand the overall utilization of this method.
 

Keywords 

estradiol pellet implantation, pellet, sex hormone deficiency, testosterone pellet implantation

Twenty-three postmenopausal women with a median of 2 years past menopause (range, 1 to 12 years) and a median age of 52 years (range, 39 to 62 years) were recruited to participate in a longitudinal study designed to investigate the factors that influence the increase in bone density with subcutaneous estradiol and testosterone implants.

SAN DIEGO, CA — Two new studies muddy waters on the potential cardiovascular risks previously linked to testosterone-replacement therapy in men, with both studies suggesting the therapy might not be causing the cardiovascular harm suggested in previous analyses. Both are scheduled for the presentation later this week at the American College of Cardiology (ACC) 2015 Scientific Sessions.

Hormone replacement therapy by pellet implantation has been used with great success in the United States, Europe and Australia since 1938 and found to be superior to other methods of hormone delivery (Greenblatt 49, Mishnell 41, Cantrill 84, Stanczyk 88). It is not experimental.

LAS VEGAS --- Contrary to recent findings, a new retrospective study of data from 40 specialized clinics around the United States has found that testosterone therapy in men is not associated with an increased risk for myocardial infarction (MI) or stroke and may even be cardioprotective.

Ten Reasons to be Happy About Hormone Replacement Therapy

In spite of the negative press reports following the 2002 Women’s Health Initiative (WHI) publication, women can be reassured that in the correct circumstances, hormone replacement therapy (HRT) is beneficial and safe, particularly if treatment is started below the age of 60.

In a new study, post-menopausal women in testosterone in theraphy showed a significant improvement in verbal learning and memory, offering a ver promising avenue of research into memory and ageing.

There are hundreds of studies correlating the development of heart disease with low testosterone levels. One, conducted by researchers from Columbia University’s College of Physicians and Surgeons, found that people with low concentrations of testosterone in the blood were more likely to have atherosclerosis documented by angiography.

During the past few years, serious concern has been raised about the safety of combined estrogen/progestogen hormone therapy in particular about its effects on the breast. Several observations suggest that androgens may counteract the proliferative effects of estrogen and progestogen in the mammary gland.

In the 1980s and 1990s the number one prescription medication in the United States was the estrogen-based menopausal treatment, Premarin. For decades, women with symptoms of menopause found improved quality of life with hormone replacement.

To investigate the role of androgens in increasing bone density and improving low libido in postmenopausal women, we have studied the long-term effects of estradiol and testosterone implants on bone mineral density and sexuality in a prospective, 2 year, single-blind randomised trial.